This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
QIAGEN Unveils Liquid Biopsy Workflows & Panels, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
QIAGEN Partners With Tecan to Advance QFT-Plus Diagnostic Test
by Zacks Equity Research
QIAGEN (QGEN) believes that the partnership will aid in improvising the automation of pre-analytic manual steps, leading to its QuantiFERON-TB Gold Plus test.
Why Is Qiagen (QGEN) Up 8.1% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intuitive Surgical Gets FDA Nod for Ion Endoluminal System
by Zacks Equity Research
The regulatory go-ahead for the Ion platform is likely to provide Intuitive Surgical (ISRG) a competitive edge in the minimally-invasive-care space.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
QIAGEN's (QGEN) Q4 Earnings In Line, Revenues Miss Mark
by Zacks Equity Research
QIAGEN's (QGEN) suffers sluggish sales at Americas. However, the company delivers strong global growth.
Qiagen (QGEN) Q4 Earnings Meet Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 0.00% and -1.43%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands
by Zacks Equity Research
QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.
QIAGEN Scores on Strategic Alliances, Suffers Low HPV Sales
by Zacks Equity Research
QIAGEN (QGEN) pins high hopes on its strategic tie-ups with Hamilton and DiaSorin. It unveils a CE-marked DiaSorin automation solution in Europe to use the LIAISON system for test read-out.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
QIAGEN Partners With Novartis to Expand CDx Tests Suite
by Zacks Equity Research
QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
by Zacks Equity Research
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
QIAGEN's New Offerings to Broaden Hematology Testing Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to progress with test menu expansion.
Qiagen (QGEN) Down 3.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences Offers Insights on Aedes aegypti Genome
by Zacks Equity Research
Pacific Biosciences (PACB) uses its flagship Single Molecule, Real-Time technology to sequence the highest quality genome assembly for the Aedes aegypti mosquito.
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
Illumina (ILMN) Inks $1.2B Deal to Buy Pacific Biosciences
by Zacks Equity Research
Illumina (ILMN) taking out on its peer, in the $1.2-billion acquisition deal, will further strengthen the position of the former in the genomics market.
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.
Qiagen (QGEN) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite
by Zacks Equity Research
QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.